Vivek Subbiah: Implementing NES and PHG in Healthcare Systems
Vivek Subbiah shared a post on X:
”Hot off the press.
Authors: Denis Horgan, Filippo Pesapane, Marc Van der Buckle, Ruggero de Maria, France Dube, Jaya Singh, Iwona Lugowska, Arnaud Bayle, Paul Hofman, Umberto Malapelle, Tanya Hills, Ettore D. Capoloungo, Vivek Subbiah.
An effective developmental blueprint is imperative to incentivize healthcare systems to integrate Next Generation Screening (NGS) and Public Health Genomics (PHG) seamlessly. This paper presents two distinct sets of metrics aimed at facilitating this integration process. One set pinpoints technical voids requiring attention to facilitate the adoption of NGS/liquid biopsy, while the other sheds fresh light on the accomplishments of national systems in their integration efforts.”
Source: Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023